PharmaEssentia Corporation (LUX:261280558)

Luxembourg flag Luxembourg · Delayed Price · Currency is EUR · Price in USD
22.80
-0.40 (-1.72%)
At close: Feb 6, 2026
Market Cap7.23B +2.5%
Revenue (ttm)386.25M +66.0%
Net Income134.33M +160.3%
EPS0.36 +159.0%
Shares Outn/a
PE Ratio53.84
Forward PE37.85
Dividend0.02 (0.08%)
Ex-Dividend DateAug 11, 2025
Volumen/a
Average Volumen/a
Openn/a
Previous Close23.20
Day's Rangen/a
52-Week Range13.58 - 24.60
Betan/a
RSI65.45
Earnings DateFeb 25, 2026

About PharmaEssentia

PharmaEssentia Corporation, a biopharmaceutical company engages in treatment for human diseases in Taiwan and internationally. Its products include Ropeginterferon alfa-2b that is used for the treatment of chronic myelogenous leukemia, T-Cell leukemia, early myelofibrosis, polycythemia vera, and essential thrombocythemia. The company also develops TCRT, anti PD-1, PEG-cytokine X,Y, and novel checkpoint abs for the treatment of solid tumors; P1101 + anti PD-1 for the treatment of hepatocellular carcinoma; and PEG-GCSF for the treatment of neutro... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 1990
Employees 131
Stock Exchange Luxembourg Stock Exchange
Ticker Symbol 261280558
Full Company Profile

Financial Performance

Financial numbers in TWD Financial Statements